Today announced that fresh data from its obesity program will be presented at Weight problems 2009.

Amylin Pharmaceuticals to provide fresh data from its obesity program at Obesity 2009 Amylin Pharmaceuticals, Inc. today announced that fresh data from its obesity program will be presented at Weight problems 2009, the 27th Annual Scientific Meeting of The Obesity Culture, to be kept in Washington, D.C intagra.org http://intagra.org . October 24-28. Stage 2 data from the pramlintide/metreleptin mixture treatment clinical program will be the subject of a late-breaking oral display. Obesity 2009 is one of the largest scientific conferences in neuro-scientific obesity. Amylin will also present brand-new scientific findings from preclinical studies linked to its clinical-stage weight problems applications for pramlintide/metreleptin and davalintide, an optimized amylin analog.

50mg per day

Data from this scholarly study could be presented in a future medical forum. Davalintide Status Update Amylin in addition has completed a Phase 2 study of davalintide, a second-generation analog of amylin, for the treatment of obesity. In this scholarly study, the weight reduction tolerability and efficacy profile of davalintide had not been improved over pramlintide, and was inferior to that of the pramlintide/metreleptin combination. Predicated on this given information, Amylin and Takeda, as part of their commercialization and co-development agreement, have decided to halt further advancement of davalintide at this time. Supply Amylin Pharmaceuticals, Inc..